It was a pleasure to catch up with Prof. Detlef Schuppan (Mainz University Medical Center, Mainz, Germany) following his presentations at virtual UEG week to discuss the current unmet needs in the treatment of celiac disease and advances being made in its management.
His presentation entitled ‘ORAL INHIBITOR OF TISSUE TRANSGLUTAMINASE PREVENTS MUCOSAL DAMAGE IN CELIAC PATIENTS UNDERGOING GLUTEN CHALLENGE’ was given at UEG Week Virtual, 3-5 Oct 2021.
- What are the unmet needs in the management of patients with celiac disease? (0:15)
- How has our increased understanding of the pathogenesis of celiac disease guided the development of novel strategies? (1:43)
- What novel approaches are being investigated in clinical trials into the management of celiac disease? (2:58)
Disclosures: Prof. Detlef Schuppan has no personal financial interests in relation to the content of this video interview; however, discloses scientific-clinical activities with research support from Zedira, Falk Pharma, Topas Therapeutics, Calypso and DFG.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Gina Furnival.
Filmed in coverage of UEG Week Virtual, 3-5 Oct 2021.
Share this Video
Related Videos In Digestive Disorders
UEG Young Talent Group – aims, key achievements and opportunities for early career gastroenterologists: Pilar Acedo
The UEG Young Talent Group (YTG) encourages young gastroenterologists to develop their careers through education, networking and training. We were delighted to catch up with UEG YTG Chair Dr. Pilar Acedo to discuss the training, education and professional opportunities available to young digestive healthcare specialists through UEG, the aims and key achievements of the UEG […]
Highlights from Digestive Disease Week 2023: Gil Y. Melmed
Digestive Disease Week took place between 6-9 May, in this touchIMMUNOLOGY interview, we caught up with our Expert Faculty member Prof. Gil Y. Melmed (Cedars-Sinai, Los Angeles, CA, USA) around his personal highlights from this year’s conference including non-pivotal clinical trial data analysing established inflammatory bowel disease (IBD) therapies such as vedolizumab, data around the […]
Comparison study of upadacitinib and tofacitinib as induction treatment in ulcerative colitis: Gil Y. Melmed, DDW 2023
Upadacitinib and tofacitinib are both JAK inhibitors (JAKis) approved by the FDA for the treatment of ulcerative colitis. In this interview with Expert Faculty member Prof. Gil Y. Melmed (Cedars-Sinai, Los Angeles, CA, USA) we discuss the aims, design and findings from his study presented at DDW 2023, comparing the efficacy and safety of these […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!